|Day Low/High||136.65 / 138.51|
|52 Wk Low/High||118.62 / 148.99|
On the 14th anniversary for 'Mad Money', Jim Cramer talks about how to balance owning index funds and individual stocks.
Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.
Jim discusses Johnson & Johnson, recent analyst notes on Apple, the cloud kings, and more!
Loss is latest setback for company's attempts to defuse thousands of claims against it alleging carcinogens in its signature baby powder caused cancer.
In this day and age, companies must be 'disruptors' or get left in the dust.
The bull market just had its 10-year anniversary but the gains have not been evenly distributed. A small number of stocks have been the main drivers, and some of these names are not what you might expect.
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
With China reducing its GDP forecast and Europe's central bank growing cautious, markets turned lower this week.
Jim Cramer's watching six stocks to determine when the selling will end.
Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.
Allergan wants Botox licenses for pediatric patients.
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
The Dow Jones Industrial Average ended the day lower as details over the trade talks between the U.S. and China are awaited and oil prices tumble.
Sales of the drug for treatment-resistant depression might not be material this year, but should act as an additional driver to J&J's already above-market growing pharmaceutical franchise.
Johnson & Johnson received FDA approval for a nasal spray designed to treat patients with depression.
Jim discusses the FDA approval of J&J's esketamine drug, the importance Disney's direct-to-consumer initiative, why you can't take your cue from a stock, and provides a view of Amgen.
Johnson & Johnson shares were rising Wednesday after the U.S. Food & Drug Administration approved a controversial antidespressant treatment, the first in three decades, even as it cautioned against potential misuse.
GE is getting slammed, Dollar Tree's earnings impressed investors, and Johnson & Johnson gets FDA approval for an anti-depressant. Here's what Jim Cramer thinks.
GE's getting hit in the markets, Johnson & Johnson gets a win from the FDA and Dollar Tree's weak forecast.
U.S. stock futures tilt lower as investors eagerly await new details on trade talks between the U.S. and China; Johnson & Johnson gets FDA approval for a nasal spray for patients with hard-to-treat depression; GE extends losses after CEO Larry Culp says he expects negative cash flow in 2019 for the company's industrial division.
Jim breaks down the Salesforce.com action and explains why the digital transformation story still has significant legs to it. Then he compares the selling in CRM to what has happened in the past to several other names.
FAANG rallies are fine when breadth is playing along. FAANG rallies that suck the life out of other stocks (breadth) to feed themselves are bearish.
Markets end volatile week little changed in spite of failed North Korea summit, and congressional testimony from Powell, Lighthizer and Cohen.
Jim discusses the positive Johnson & Johnson news related to asbestos not being found at its baby powder plants in India, yesterday's selloff in the MCOs, the market, trade with China after this morning's interview with Larry Kudlow, and more!
Government regulators tested the company's baby talcum powder to determine whether it contained asbestos.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.